ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy (previously referred to as ARS-1) for the emergency treatment of Type I allergic reactions, including anaphylaxis.
| Year | Equity | Revenue | EBITDA | Fin. Res. | Net Inc. | Net Mar. | ROE | Cash | Debt | N.D. / EBITDA | OCF | CAPEX | FCF | Free | Div. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/23 TTM | 261 | 1 | -47 | 0 | -42 | L | L | 265 | 0 | L | -46 | 0 | 193 | -46 | 0 |
The values above are represented in USD and the scale is in millions—10.000 is the equivalent of 10 billions. L inside the table means Loss.